SGEN Seattle Genetics Inc.

79.2
+2.49  (+3%)
Previous Close 76.71
Open 77.67
Price To Book 10.08
Market Cap 12,808,238,335
Shares 161,720,181
Volume 548,715
Short Ratio
Av. Daily Volume 1,065,401

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated.
SGN-LIV1A (I-SPY 2)
Neoadjuvant for newly diagnosed Stage 2 or 3 HER2 negative breast cancer
Phase 1/2 trial initiated early 2018.
SGN-LIV1A + KEYTRUDA
First-line triple negative breast cancer (TNBC)
Phase 2 data due 1H 2020.
Tisotumab Vedotin (innovaTV 204 )
Cervical Cancer
Phase 2 pivotal data noted 44% ORR. CR rate 12%. BLA filing due 2019.
Enfortumab vedotin - EV201
Urothelial cancer
Phase 3 trial initiated 2Q 2017.
ADCETRIS and Opdivo
Relapsed Hodgkin Lymphoma
Phase 3 trial initiated mid-2017. Data from Phase 1/2 at ASH 2017 showed a 83% ORR and 62% CR.
ADCETRIS and Opdivo CM-812
Relapsed Hodgkin Lymphoma
Approval announced August 19, 2011.
ADCETRIS
Hodgkin lymphoma and Anaplastic large cell lymphoma
Phase 1/2 clinical hold placed on December 27, 2016 was lifted March 6, 2017. Enrollment halted June 19, 2017 due to safety.
Vadastuximab Talirine (SGN-CD33A)
Myelodysplastic syndrome (MDS)
Phase 1b updated data at SABCS December 7, 2017.
(Tucatinib ONT-380) and T-DM1
HER2+ Metastatic Breast Cancer (MBC)
Phase 2 data due 2H 2019.
(Tucatinib ONT-380) + Herceptin and Xeloda - HER2CLIMB trial
HER2+ Metastatic Breast Cancer (MBC)
Phase 3 trial discontinued due to higher rate of deaths - June 19, 2017.
Vadastuximab Talirine (CASCADE)
Acute myeloid leukemia (AML) - cancer
sBLA approval announced March 20, 2018. PDUFA date under priority review was May 1, 2018.
ADCETRIS in combination with chemotherapy ECHELON-1
Frontline Hodgkin lymphoma
Phase 2 trial initiated 3Q 2016.
SGN-CD19A
Frontline DLBCL cancer
FDA Approval announced November 16, 2018.
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
Approved August 17, 2015 under priority review.
ADCETRIS - AETHERA
Post-transplant Hodgkin lymphoma (HL) cancer
Approval announced November 9, 2017.
ADCETRIS
Cancer - ALCANZA trial for relapsed CD30-positive cutaneous T-cell lymphoma
Phase 1b trial has been initiated - noted February 6, 2018.
Enfortumab vedotin and pembrolizumab
2nd-line Urothelial cancer
Phase 1b/2 trial has been initiated.
Ladiratuzumab Vedotin
Triple negative breast cancer (TNBC)
Phase 3 trial initiation announced July 9, 2018.
Enfortumab vedotin - EV-301
Urothelial cancer
Phase 2 dosing has commenced - noted July 12, 2018.
Tisotumab Vedotin (innovaTV 207)
Solid tumors
Phase 1/2 updated data presented at ESMO October 20. 2018.
Tisotumab Vedotin (innovaTV 201)
Recurrent Cervical Cancer
Phase 1 data February 11, 2019 noted ORR 42%.
Enfortumab vedotin EV-101
Urothelial cancer
FDA approval announced June 10, 2019.
Polatuzumab vedotin and bendamustine plus Rituxan (rituximab)
Diffuse large B-cell lymphoma (DLBCL)
Phase 2 presentation at EHA June 15, 2019.
ADCETRIS and Opdivo CM-744
Relapsed/Refractory Classical Hodgkin Lymphoma
Phase 1/2 initial data due 2019.
Enapotamab vedotin
Solid tumors

Latest News

  1. Alder BioPharmaceuticals approaches rare status for a Seattle biotech
  2. Why Is Seattle Genetics (SGEN) Up 2.4% Since Last Earnings Report?
  3. Seattle Genetics Inc (SGEN) President and CEO Clay B Siegall Sold $1.5 million of Shares
  4. Top Biotech Stocks for February 2019
  5. Seattle Genetics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
  6. Seattle Genetics Announces Pricing of Public Offering of Common Stock
  7. Seattle Genetics Announces Proposed Public Offering of Common Stock
  8. Jim Cramer Weighs In On Berkshire Hathaway, Range Resources, Zynerba And More
  9. Seattle Genetics Has a Rally in Its DNA
  10. 3 “Perfect 10” Biotech Stocks to Buy
  11. Edited Transcript of SGEN earnings conference call or presentation 16-Jul-19 8:30pm GMT
  12. Seattle Genetics Hits Its Second Growth Phase
  13. Why Seattle Genetics, AVROBIO, and First Majestic Silver Jumped Today
  14. Here's Why Seattle Genetics Rocketed Higher Today
  15. Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates
  16. Seattle Genetics Inc (SGEN) Q2 2019 Earnings Call Transcript
  17. Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates
  18. The Surprising Reason This Biotech Stock Got An After-Hours Boost
  19. Seattle Genetics Reports Second Quarter 2019 Financial Results
  20. Seattle Genetics, Inc. to Host Earnings Call